This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

More Than a Gut Reaction: Effective Strategies to Treat and Prevent Recurrent <em>C. Difficile</em> Infection

More Than a Gut Reaction: Effective Strategies to Treat and Prevent Recurrent C. Difficile Infection

Format

Meeting Coverage

Time to Complete

1.50 hours

Released

September 1, 2016

Expires

September 1, 2017
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / ANCC Contact Hours
1.50 / CPE Contact Hours

Accredited Provider

Jointly provided by Rush University Medical Center and Interprofessional Continuing Education.

Commercial Supporter

Supported by an educational grant from Merck & Co Inc.

Program Description

Clostridium difficile causes approximately 500,000 infections in the United States per year, with 83,000 of these patients experiencing at least one recurrence, and 29,000 patients dying within 30 days of initial diagnosis. Effective treatment varies for patients with initial infection, severe, complicated infection, and recurrent infection, and identification of those at highest risk of recurrence is critical in order to prevent devastating complications. This archived symposium will offer participants the opportunity to evaluate all facets of patients with initial and recurrent C difficile infection (CDI), including assessment of existing and emerging therapies, as they develop customized treatment plans via interactive case scenarios.

Intended Audience

This archived symposium is designed to meet the educational needs of infectious disease specialists, gastroenterologists, surgeons, and other healthcare providers who are involved in the care of patients with CDI.

Educational Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • DISCUSS the evolving epidemiology of C. difficile infection and recurrent C. difficile infection.
  • INTEGRATE best practice antibacterial regimens for treatment of patients with C. difficile infection.
  • DESCRIBE emerging modalities to prevent and treat recurrent C. difficile infection.

Conflict Of Interest Disclosure Policy

In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Faculty

Ciarán P. Kelly, MD (Course Director)
Professor of Medicine
Harvard Medical School
Director, Gastroenterology Fellowship Training
Medical Director, Celiac Center
Beth Israel Deaconess Medical Center
Boston, MA

Dr. Kelly reports receiving research support from the National Institutes of Health, Entera Health Inc, and Institut Merieux; receiving royalties from UpToDate.com; serving as a consultant for Merck & Co Inc, Seres Therapeutics, Summit, and Synthetic Biologics Inc; and receiving salary from Beth Israel Deaconess Medical Center and Harvard Medical School.

Dale N. Gerding, MD
Professor of Medicine, Infectious Diseases
Loyola University Chicago Stritch School of Medicine
Research Physician, Edward Hines Jr VA Hospital
Hines, IL

Dr. Gerding reports serving as a consultant for Actelion Pharmaceuticals, Da Volterra, Merck & Co Inc, Pfizer Inc, Rebiotix Inc, SanofiPasteur, Summit, and ViroPharm/Shire.

Carlene A. Muto, MD, MS
Medical Director of Infection Prevention and Hospital Epidemiology
University of Pittsburgh Medical Center (UPMC)
Presbyterian Center for Quality, Safety, and Innovation
UPMC Health System
Associate Professor of Medicine and Epidemiology
Division of Infectious Diseases
University of Pittsburgh School of Medicine
Pittsburgh, PA

Dr. Muto reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

John Segreti, MD
Professor of Medicine
Division of Infectious Diseases
Rush Medical College
Chicago, IL

Dr. Segreti reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation Statement

Rush University Medical Center designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This enduring material has been produced in compliance with all ACCME Essential Areas and Elements and Accreditation Policies. This activity is being presented without bias and with commercial support.

Credit

1.50

Type

CE for Nurses

Accreditation Statement

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this CE activity is 1.50 contact hours.

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation Statement

Rush University Medical Center designates this knowledge based CPE activity (0622-0000-16-001-H01-P) for 1.5 contact hours for pharmacists.

Disclosure of Unlabeled Use

In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

Instructions

In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the posttest. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue